FIELD: biochemistry.
SUBSTANCE: invention relates to the use of a programmed death protein ligand 1 (PD-L1) antagonist in combination with a VEGFR inhibitor for treating cancer associated with VEGFR and PD-L1 in a subject. Also disclosed is the use of a drug and a kit containing said combination.
EFFECT: invention makes it possible to effectively treat cancer associated with VEGFR and PD-L1.
22 cl, 3 dwg, 10 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| POLYFUNCTIONAL PROTEIN MOLECULES CONTAINING DECORIN AND USE THEREOF | 2019 |
|
RU2823357C2 |
| AVELUMAB DOSING MODE FOR TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2777363C2 |
| ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | 2019 |
|
RU2826084C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| BISPECIFIC ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND METHOD FOR PRODUCTION THEREOF | 2021 |
|
RU2818312C1 |
